Hexahydro Cannabinoid Agonist

The natural occurrence of cannabinoids in Cannabis sativa has been known for centuries. However, it was not until the early 1990s that the first cannabinoid receptor (CB) was identified and the endocannabinoid system characterized. The discovery of this system has significantly enhanced our understanding of how cannabinoids exert their effects. The CB receptors are widely expressed in the brain and other organs, and activation of these receptors results in a variety of physiologic responses, including changes in mood, pain perception, appetite, and memory.

Since then synthetic cannabinoids have been developed to specifically target these receptors without cannabis’ negative side-effects. Cannabinoids bind to two types of cannabinoid receptors: CB-type I (CB-I) and CB-type II (CB-II). The CB-I receptor is primarily found in the brain and mediates psychotropic activity while the CB-II receptor, which occurs mainly peripherally, regulates inflammatory processes.

What is Hexahydro?

In case you don’t know, Hexahydrocannabinol, also known as THC which is the hydrogenated derivative of tetrahydrocannabinol.

What is Hexahydro Cannabinoid Agonist?

The connection between obesity and the endocannabinoid system, as well as the CB1 receptor antagonist/inverse agonist rimonabant’s development as an anti-obesity agent, were two of the major reasons for its usage.

To sum up

The Hexahydro Cannabinoid Agonist is an important understanding when it comes to the world on cannabinoids. If you have further questions, please contact us to let us share the latest news with you.

Hexahydro Cannabinoid Agonist